Company
Overview
	 Gifford Bioscience Limited is a contract research organization 
	(CRO) performing preclinical and discovery pharmacology services for biotech, pharma 
	and academic investigators.  The company originally began in 2008 as Invivopharm Inc, a CRO based on radiometric receptor pharmacology studies, and this continues as the core focus of the company.  Our studies are performed in vitro
	in cell and membrane preparations and ex vivo in human and rodent tissues.
	Focused services and a deep experience with our assays assures clients of quick turnaround times and the highest quality 
	results.
Gifford Bioscience Limited is a contract research organization 
	(CRO) performing preclinical and discovery pharmacology services for biotech, pharma 
	and academic investigators.  The company originally began in 2008 as Invivopharm Inc, a CRO based on radiometric receptor pharmacology studies, and this continues as the core focus of the company.  Our studies are performed in vitro
	in cell and membrane preparations and ex vivo in human and rodent tissues.
	Focused services and a deep experience with our assays assures clients of quick turnaround times and the highest quality 
	results.
Management
Andrew Gifford, Ph.D. - Chief Scientific Officer and Chairman
 Andrew was previously a Senior Scientist in the 
	radiopharmaceutical development program at Brookhaven National Laboratory, 
	New York. As a Principal Investigator, he has been responsible for the 
	preclinical development of a variety of radiolabelled drugs. Techniques 
	employed in his academic laboratories were primarily  radiolabeling chemistry, ligand 
	binding and occupancy assays and tissue autoradiography.  Andrew is a graduate of Imperial College, London 
	and was awarded his PhD in Pharmacology by the University of St. Andrews. He is an 
	author on 51 peer-reviewed publications.
	Selected publications
Andrew was previously a Senior Scientist in the 
	radiopharmaceutical development program at Brookhaven National Laboratory, 
	New York. As a Principal Investigator, he has been responsible for the 
	preclinical development of a variety of radiolabelled drugs. Techniques 
	employed in his academic laboratories were primarily  radiolabeling chemistry, ligand 
	binding and occupancy assays and tissue autoradiography.  Andrew is a graduate of Imperial College, London 
	and was awarded his PhD in Pharmacology by the University of St. Andrews. He is an 
	author on 51 peer-reviewed publications.
	Selected publications
Mr Macer Gifford - Chief Executive Officer and Managing Director
 Macer is a banker by profession. His career has spanned 
	numerous senior roles, including Deputy Group CEO at Ahli United and Group 
	Head of Regional Markets at Standard Chartered. Macer is a graduate of 
	the London School of Economics and a Sloan Fellow of the London Business 
	School.
Macer is a banker by profession. His career has spanned 
	numerous senior roles, including Deputy Group CEO at Ahli United and Group 
	Head of Regional Markets at Standard Chartered. Macer is a graduate of 
	the London School of Economics and a Sloan Fellow of the London Business 
	School.
Allison Liu, Ph.D., VP, Research Operations
Dr. Liu received a Ph.D. in genetics from Cold Spring Harbor and performed postdoctoral training in the area of neurodegeneration at Rockefeller University. She previously was a staff scientist in the Medical Department at Brookhaven National Laboratory.
Facilities
 Taking 
	advantage of an EU grant, we recently relocated to modern laboratory space 
	in the Birmingham Research Park, next to the University of Birmingham, U.K.. 
	Our facilities include a variety of standard and specialized research 
	equipment, tissue culture and a broad radioactive substances permit. We 
	additionally have access to animal housing via the University and to fresh 
	post-surgical human tissues via the Human Biomaterials Resource Centrer at 
	the Birmingham Queen Elizabeth Hospital.
Taking 
	advantage of an EU grant, we recently relocated to modern laboratory space 
	in the Birmingham Research Park, next to the University of Birmingham, U.K.. 
	Our facilities include a variety of standard and specialized research 
	equipment, tissue culture and a broad radioactive substances permit. We 
	additionally have access to animal housing via the University and to fresh 
	post-surgical human tissues via the Human Biomaterials Resource Centrer at 
	the Birmingham Queen Elizabeth Hospital.
Visits to our laboratory are welcome.
 
	 
